Combination of sirtuin 3 and hyperoxia diminishes tumorigenic properties of MDA-MB-231 cells

Iva I Podgorski1, Marija Pinterić1, Dora Marčinko1

  • 1Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.

Life Sciences
|May 20, 2020
PubMed
Abstract

Insights

Sirtuin 3 (Sirt3) and hyperoxia negatively impact triple-negative breast cancer (TNBC) cells. This combined effect, along with individual impacts, suggests potential therapeutic strategies for TNBC.

Area of Science:

  • Mitochondrial biology
  • Cancer research
  • Cellular metabolism

Background:

  • Sirtuin 3 (Sirt3) plays a complex role in cancer.
  • Hyperoxia, or high oxygen levels, typically suppresses tumors.
  • The interaction between Sirt3 and hyperoxia in triple-negative breast cancer (TNBC) is not well understood.

Purpose of the Study:

  • To investigate the role of Sirt3 in MDA-MB-231 TNBC cells under hyperoxic conditions.
  • To determine the combined effects of Sirt3 and hyperoxia on TNBC cell behavior.

Main Methods:

  • Stable transfection of MDA-MB-231 cells with Sirt3 or empty plasmid.
  • Analysis of mitochondrial biogenesis, metabolic regulation, and antioxidant defense markers via Western blot and qPCR.
  • Assessment of mitochondrial function, reactive oxygen species (ROS) production, metabolic activity, proliferation, DNA damage, and apoptosis using flow cytometry, MTT assays, and other cellular assays.

Main Results:

  • Sirt3 enhanced mitochondrial properties but also increased ROS, DNA damage, and apoptosis, ultimately reducing proliferation.
  • Hyperoxia exacerbated these effects, indicating a combined negative impact on TNBC cells.
  • The Warburg effect and antioxidant defenses (SOD2, Cat) were modulated by Sirt3.

Conclusions:

  • Both Sirt3 and hyperoxia, individually and combined, demonstrate potential to inhibit malignant properties of MDA-MB-231 cells.
  • These findings suggest Sirt3 and hyperoxia as potential therapeutic avenues for TNBC.
  • Further research is warranted to explore their clinical applicability in TNBC treatment.